Piulats Rodriguez, J. M., Piperno-Neumann, S., Rutkowski, P., Nathan, P., Hassel, J. C., Espinosa, E., … Baurain, J.-F. (2022). 823P A propensity score weighted comparison of tebentafusp or pembrolizumab versus combination ipilimumab and nivolumab in untreated metastatic uveal melanoma. In Annals of Oncology (Vol. 33, pp. S924–S924). Elsevier BV. https://doi.org/10.1016/j.annonc.2022.07.949

Piulats Rodriguez, J. M., S. Piperno-Neumann, P. Rutkowski, P. Nathan, J. C. Hassel, E. Espinosa, L. de la Cruz Merino, et al. “823P A propensity score weighted comparison of tebentafusp or pembrolizumab versus combination ipilimumab and nivolumab in untreated metastatic uveal melanoma.” In Annals of Oncology, 33:S924–S924. Elsevier BV, 2022. https://doi.org/10.1016/j.annonc.2022.07.949.

Piulats Rodriguez JM, Piperno-Neumann S, Rutkowski P, Nathan P, Hassel JC, Espinosa E, et al. 823P A propensity score weighted comparison of tebentafusp or pembrolizumab versus combination ipilimumab and nivolumab in untreated metastatic uveal melanoma. In: Annals of Oncology. Elsevier BV; 2022. p. S924–S924.

Piulats Rodriguez, J. M., et al. “823P A propensity score weighted comparison of tebentafusp or pembrolizumab versus combination ipilimumab and nivolumab in untreated metastatic uveal melanoma.” Annals of Oncology, vol. 33, Elsevier BV, 2022, pp. S924–S924. Crossref, doi:10.1016/j.annonc.2022.07.949.

Piulats Rodriguez JM, Piperno-Neumann S, Rutkowski P, Nathan P, Hassel JC, Espinosa E, de la Cruz Merino L, Ochsenreither S, Shoushtari AN, Orloff M, Salama AKS, Watkins C, Goodall H, Baurain J-F. 823P A propensity score weighted comparison of tebentafusp or pembrolizumab versus combination ipilimumab and nivolumab in untreated metastatic uveal melanoma. Annals of Oncology. Elsevier BV; 2022. p. S924–S924.